News | May 26, 2010

Boston Scientific Plans Stent Rematch With Xience

May 26, 2010 – In the constantly evolving battle for the best coronary stent, Boston Scientific said today it initiated the PLATINUM PLUS clinical trial, comparing its next-generation Promus Element everolimus-eluting coronary stent to the Xience Prime everolimus-eluting coronary stent.

Data from the SPIRIT IV trial released last fall showed Abbott’s Xience V had advantages over Boston’s Taxus Express, which allowed Xience to capture the top market position. This new trial will pit the next-generation stent platforms from both Abbott and Boston, in which Boston eventually hopes to reclaim market share.

The Promus Element Stent, which received CE mark in October 2009, is Boston Scientific's third-generation drug-eluting stent technology and incorporates a platinum chromium alloy with a new stent design and a new catheter delivery system.

The investigator-sponsored research study is a prospective, randomized, multicenter clinical trial with planned enrollment of 2,980 patients at 50 sites in France, Germany, Italy, Spain and the U.K. It will evaluate coronary revascularization outcomes in an unrestricted patient population randomized (2:1) to receive a Promus Element stent or Xience Prime stent. The primary endpoint is 12-month target vessel failure with planned follow-up out to 34 months. The trial is funded by a research grant from Boston Scientific and led by Principal Investigator Jean Fajadet, M.D., Clinic Pasteur, Toulouse, France and Co-principal Investigator Eulogio Garcia, M.D., Clinico San Carlos, Madrid, Spain. Results are expected to be presented in 2012.

"We are very enthusiastic about beginning the first large-scale randomized trial that compares the new platinum chromium Promus Element stent with the Xience Prime stent," said Fajadet. "The results should demonstrate how two distinct stent platforms, with the same everolimus drug, perform in a head-to-head comparison."

The Promus Element is designed specifically for coronary stenting. The stent architecture and proprietary platinum chromium alloy combine to offer greater radial strength and flexibility. The stent architecture helps create consistent lesion coverage and drug distribution while improving deliverability, which is enhanced by an advanced catheter delivery system. The higher density alloy provides superior visibility and reduced recoil while permitting thinner struts compared to prior-generation stents.

The PLATINUM PLUS trial is coordinated by the Centre Europeen de Recherche Cardiovasculaire (CERC) under the direction of Marie-Claude Morice, M.D. CERC is an interventional cardiology clinical research organization based in Paris.

"This is an important study that could provide insights on the potential benefits of third-generation drug-eluting stents in an all-comers trial reflecting the daily clinical practice of interventional cardiologists," Morice said.

The PLATINUM PLUS trial will provide data that may complement Boston Scientific's PLATINUM clinical trial, which completed enrollment of 1,531 patients at 133 sites worldwide in September 2009. PLATINUM is a randomized, controlled, pivotal trial designed to support U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the Promus Element.
The company hopes for FDA approval for the Taxus Element stent in mid-2011 and for the Promus Element in mid-2012. It expects MHLW approval for the Taxus Element in late 2011 or early 2012 and for the Promus Element in mid-2012.

In the United States the Promus Element and Taxus Element are investigational devices and are limited by applicable law to investigational use only and are not available for sale.

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init